AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail.
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan received US FDA Fast Track designation for advanced or metastatic non-squamous NSCLC patients who have undergone prior systemic therapy.
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, received US FDA Fast Track designation for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior systemic therapy. The designation is based on the TROPION-Lung01 Phase III trial, which showed a significant improvement in progression-free survival compared to standard chemotherapy.
This Fast Track designation could expedite the development and review of datopotamab deruxtecan, potentially bringing a new treatment option to a large patient population with advanced lung cancer who have limited choices after initial therapies fail. It strengthens AstraZeneca and Daiichi Sankyo's position in the competitive ADC market for oncology.
Where this signal fits in the broader landscape.
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.astrazeneca.com/media-centre/press-releases/2026/datopotamab-deruxtecan-granted-fast-track-designation-in-us-for-metastatic-non-small-cell-lung-cancer.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In